FDA Class 2 Medical Device: Everything You Need to Know

If you imagine the FDA’s medical-device rulebook as a three-lane highway, Class II sits in the middle lane—devices that carry more risk than a tongue depressor but far less than a heart valve. By FDA count, there are over 1,700 individual device types, grouped into 16 clinical specialty “panels,” and roughly 800 of those fall into the Class II, moderate-risk bucket.  

What makes a device Class II is not the marketing pitch or price tag, but the regulatory math: general controls (registration, labeling, QSR, MDR, etc.) plus an extra layer of “special controls”—performance standards, specific labeling, post-market surveillance, or test protocols—needed to assure safety and effectiveness. 

For innovators, that translates to a predictable yet evidence-driven path: document your design under Quality System Regulation, prove substantial equivalence (or pursue De Novo), satisfy any device-specific special controls, and you can reach the market without the full Premarket Approval burden reserved for Class III. This article unpacks every step—from definitions to clearance strategies—so you can navigate that middle lane with confidence and speed. 

What is a FDA Class 2 medical device

A Class 2 medical device is one the FDA deems to present “moderate risk” to patients or users—serious enough that basic “general controls” (registration, labeling, Quality System Regulation, complaint handling, etc.) are not sufficient on their own. Under §513(a)(1)(B) of the Federal Food, Drug, and Cosmetic Act, these devices must also meet “special controls” the FDA tailors to each product category—performance standards, device-specific labeling, post-market surveillance, or test-method guidance—to provide reasonable assurance of safety and effectiveness. 

In practical terms, Class 2 sits squarely between low-risk Class I and high-risk Class III products. FDA training materials note about 800 device types—from blood-pressure cuffs to infusion pumps—occupy this middle tier. Most require a Premarket Notification (510(k)) that demonstrates “substantial equivalence” to a legally marketed predicate, although certain well-understood Class 2 devices are exempt from 510(k) when the agency believes existing controls already mitigate risk. 

Bottom line: if your product’s risks can be adequately managed by general controls plus clearly defined special controls—without the exhaustive Premarket Approval demanded of Class III—you are squarely in Class 2 territory. 

How does FDA Determine Class 2 Medical Devices 

The FDA’s starting point is Section 513(a) of the Federal Food, Drug, and Cosmetic Act, which instructs the agency to match every device with the “lowest level of control that still provides reasonable assurance of safety and effectiveness.” If general controls alone are insufficient—but full Premarket Approval would be excessive—the device lands in Class II, meaning it must also meet one or more special controls such as performance standards, device-specific labeling, or post-market surveillance. 

To implement that statute, CDRH reviews each generic device type through one of 16 clinical specialty panels (e.g., Cardiovascular, Ophthalmic). The panel description published in 21 CFR Parts 862-892 lists the intended use, risk profile, and class assignment. When manufacturers consult these parts—or the product-code database—they can usually find an existing regulation that fits their device; if the cited class is II, the special controls spelled out in the accompanying regulation or guidance automatically apply. 

If no regulation exists—or emerging data suggest the original class is no longer appropriate—FDA convenes a classification panel to classify or reclassify the device. The formal sequence is: panel recommendation → Federal Register proposed rule → public comment → final classification rule. A device initially placed in Class III can be down-classified to Class II when new evidence shows that special controls adequately mitigate risk; similarly, a novel, predicate-less moderate-risk product can enter the market via the De Novo pathway, which creates a brand-new Class II regulation. 

FDA Class 2 medical device requirements 

Class II manufacturers must comply with both general controls (mandatory for all devices) and special controls (unique to Class II). Together, these create the “moderate risk” compliance framework that substitutes for the much heavier PMA burden applied to Class III. 

1 General controls – the foundation 

Pillar	Key regulation	Practical takeaway
Establishment Registration & Device Listing	21 CFR 807	Register annually, list every marketed device, and keep FDA informed of changes.
Quality System Regulation (QSR)	21 CFR 820	Design controls, purchasing controls, CAPA, and production records that collectively form your Device Master Record and DHF.
Labeling & Branding	21 CFR 801	Prevent misbranding; follow UDI rules and any device-specific warnings.
Medical Device Reporting (MDR)	21 CFR 803	File adverse event and malfunction reports (eMDR) within the mandated timelines.
Corrections, Removals & Banned Devices	21 CFR 806 & §518	Notify FDA of field actions; never market a banned device.

While most Class II devices also require a 510(k), a subset is exempt when FDA concludes the above controls alone provide adequate assurance of safety and effectiveness. Always check the exemption list before you submit.  

2 Special controls – the Class II differentiator 

Special controls are device-specific requirements published either in the device’s regulation (21 CFR Parts 862-892) or in an accompanying guidance document. They may include: 

• Performance standards – e.g., minimum insulation resistance for electrosurgical generators. 

• Bench or animal test protocols – standardized biocompatibility, electromagnetic-compatibility, or software validation methods the sponsor must follow. 

• Explicit labeling language – warnings, contraindications, or usage environment statements. 

• Post-market surveillance (Section 522 orders) – FDA can mandate follow-up studies when public-health questions remain (e.g., metal-on-metal implant registries).  

Because special controls vary by product code, manufacturers should pull the Class II Special Controls Document for their device type early in development and build test plans and labeling around those exact specifications.  

3 Economic & administrative touchpoints 

• User fees: All 510(k) and De Novo submissions incur MDUFA fees; small businesses may qualify for discounts. 

• FDA eSTAR template: Since 2023, most Class II premarket files must be submitted via eSTAR for structured data entry, reducing administrative hold times. 

• Annual registration fee: Separate from submission fees, registration fees keep FDA’s establishment database current. 

Satisfying Class II requirements means layering the universal quality and reporting rules of general controls with the special controls tailored to your specific product code—then documenting everything in a structured premarket submission. Nail those elements, and FDA clearance becomes a question of completeness rather than chance. 

Examples of a FDA class 2 medical device 

Below are representative Class II devices, each tied to its regulation number (21 CFR) and FDA product code. These examples show the breadth of “moderate-risk” technologies—ranging from patient-worn consumables to motor-driven durable equipment. 

Device (generic type)	21 CFR citation	Product code	Why it’s Class II
Blood-glucose meter & test strips	862.1345	NBW	Requires bench accuracy testing, biocompatibility, EMC, and labeling special controls to prevent dosing errors.
Infusion pump (external)	880.5725	MEB	Performance standards and software validation control flow-rate accuracy and alarm reliability.
Powered wheelchair	890.3860	ITI	Special controls include dynamic-stability, braking, and battery-safety testing, plus user-manual requirements.
Soft (hydrophilic) daily-wear contact lenses	886.5925	LPL	Optical performance, overnight-wear limits, microbial contamination tests, and specific labeling.
Surgical drape & drape accessories	878.4370	KKX/LRO	Material barrier performance, sterility assurance, and particulate-release limits governed by special controls; many are 510(k)-exempt.

If your product resembles any item on this list in purpose and risk profile, expect Class II treatment: general controls + device-specific special controls + (usually) a 510(k). 

Premarket Submission Requirements for Class II Medical Devices 

Because Class II products fall into the “moderate-risk” tier, the FDA expects most of them to arrive with a Premarket Notification—better known as a 510(k). A small subset listed in the “Class I & II Device Exemptions” database can bypass premarket review, but for the majority the following roadmap applies.  

1 Confirm the correct submission pathway 

1. Search 21 CFR Parts 862-892 or the Product-Code database to identify your device’s regulation number and class. 
2. If a predicate device exists → Traditional, Abbreviated, or Special 510(k). 
3. If no predicate exists and the risk is still moderate → De Novo Classification Request (creates a new Class II regulation). 

2 Prepare a complete 510(k) dossier (now in eSTAR) 

As of 1 October 2023, every 510(k) must be filed electronically with the interactive eSTAR template. Paper eCopies are no longer accepted for standard 510(k)s. A fully populated eSTAR package contains—at minimum—these modules: 

• Administrative information & MDUFA cover sheet (fee receipt). 

• Device description — materials, software level, key technological characteristics. 

• Indications for use & labeling — draft IFU, packaging, UDI placement. 

• Substantial-equivalence comparison — side-by-side table vs. predicate. 

• Risk analysis (ISO 14971 linkage) and design-control references. 

• Performance data 

• Bench testing (mechanical, electrical, EMC, wireless coexistence). 

• Biocompatibility (ISO 10993 matrix). 

• Software/Firmware validation (per FDA “Software Level of Concern”). 

• Sterilization/pyrogen and shelf-life studies if sterile. 

• Clinical data only if bench/animal testing cannot adequately address risk. 

• Standards & guidance conformance table (Abbreviated 510(k) may leverage recognized consensus standards). 

The eSTAR wizard flags any missing attachments before acceptance, reducing the traditional “Refuse-to-Accept” (RTA) cycle.  

3 Key alternatives and add-ons 

Scenario	Submission type	Target review clock*	Notes
Minor modification to your own cleared device	Special 510(k)	~30 days	Design-control records substitute for new test data.
Predicate exists and you rely mainly on FDA-recognized standards	Abbreviated 510(k)	≤90 days	Provide declarations of conformity plus limited data.
No predicate, moderate risk	De Novo Request	120–150 days	Creates new regulation/product code; uses eSTAR.
Low-to-moderate risk, eligible for third-party route	Third-Party 510(k)	30–60 days	FDA issues final SE letter after outsourced review.

*FDA goal dates; actual timelines depend on completeness and deficiency responses. 

4 After submission 

1. eSTAR technical screening → Receipt acknowledgement number. 
2. RTA review (15 calendar days) — missing elements trigger immediate hold. 
3. Substantive review — interactive review; address Additional-Information (AI) letters within 180 days. 
4. Decision letter: 
   1. SE = cleared to market. 
   2. NSE = option to supplement, appeal, or convert to De Novo. 
5. Maintain QSR compliance and file eMDRs once commercial distribution begins.  

For Class II devices, the 510(k) is still the workhorse pathway—but since October 2023 the eSTAR template and well-mapped performance evidence are non-negotiable. Build your dossier around the predicate comparison, satisfy every special control, and clearance becomes a predictable milestone rather than an open-ended gamble. 

Different premarket submissions for FDA class 2 devices 

Although the vast majority of Class II products reach market with a 510(k), the FDA actually offers four distinct submission routes—plus an advisory “pre-submission” option—to match different business and technical scenarios. 

Submission route	Ideal when…	Core content	Typical FDA clock *
Traditional 510(k)	A predicate device exists but your tech, materials, or software differ enough that you must provide full performance data	Complete comparison table, bench/animal testing, risk analysis, labeling	90 days goal
Abbreviated 510(k)	You conform to one or more FDA-recognized consensus standards or guidance documents that already answer most safety/effectiveness questions	Declarations of conformity + focused testing to fill any gaps	Often < 90 days
Special 510(k)	You are modifying your own previously cleared device—e.g., a design tweak, new component, or firmware update—with no change to intended use	Design-control records showing the change is properly validated and does not raise new risks	≈ 30 days
Third-Party 510(k)	Your device and product code are on the “accredited persons” list; you prefer an external reviewer to shorten FDA queue time	Same dossier as a Traditional 510(k), but first reviewed by a 3P510k organization, then spot-checked by FDA	30-60 days
De Novo Request	No predicate exists yet risk is still low-to-moderate; you need FDA to create a new Class II regulation/product code	Risk-based classification rationale + full performance package (often resembles a small PMA)	120–150 days

*Goal dates per current MDUFA V performance targets; clock stops for Additional-Information (AI) deficiencies. 

eSTAR is now mandatory for 510(k) and De Novo files 

Since 1 Oct 2023, FDA requires nearly all 510(k) submissions—and strongly encourages De Novo requests—to be built in the electronic Submission Template And Resource (eSTAR). The interactive PDF flags missing elements up-front, reducing Refuse-to-Accept holds.  

Don’t skip the Pre-Sub (Q-Submission) 

Before committing to any of these routes, sponsors can request a Pre-Submission meeting to confirm the chosen pathway, performance-test plan, and special-controls interpretation. Though optional, a Pre-Sub can shave months off the review by aligning expectations early.  

Choosing the right premarket route for a Class II device is about matching predicate availability, design changes, and timeline pressure to the submission that delivers the fastest, most predictable clearance—while still satisfying every general and special control the FDA requires. 

Approval process for Class II Medical Devices 

Here is a step-by-step guide for FDA approval process for Class II devices 

1. Pin down the classification early
   Search the product-code database or 21 CFR Parts 862-892, confirm the device is Class II, and note every “special control” listed in the regulation or accompanying guidance. This drives your test matrix and labeling from day one.  
2. Lock your regulatory strategy with FDA before you spend big
   A Pre-Submission (Q-Sub) meeting lets you show FDA your intended predicate (or De Novo rationale), performance-test plan, and cybersecurity/biocompatibility strategy. Feedback at this stage routinely saves months of rework. 
3. Generate evidence under a compliant QMS
   Design-control documentation (DHF), risk analysis (ISO 14971), bench performance, biocompatibility, software validation, EMC/wireless, sterilization, shelf-life, and any required clinical data must be complete and traceable to the hazards you identified. 
4. Build the eSTAR file—now mandatory for every 510(k)
   Since 1 October 2023, all 510(k)s—Traditional, Abbreviated, or Special—must be submitted as electronic submissions using FDA’s interactive eSTAR template. The wizard prevents omissions that would trigger a Refuse-to-Accept hold.  
5. Pay the MDUFA user fee and submit via the CDRH Portal
   A payment confirmation must appear in your eSTAR “administrative information” section. Small-business determination numbers unlock steep discounts—apply early. 
6. Administrative (RTA) review—15-day gatekeeper
   FDA screens the file for completeness. Missing sections or unsigned forms lead to an immediate Refuse-to-Accept notice, stopping the review clock before it even starts.  
7. Substantive review and interactive dialogue
   Once accepted, the file enters substantive review. For FY 2025, FDA’s performance goal is a decision in roughly 90 calendar days for a well-prepared 510(k) and 120-150 days for a De Novo.
   Expect “Additional Information” (AI) letters: you typically have up to 180 days to answer every deficiency. Provide a complete response or the submission will be withdrawn. 
8. Decision letter—green light or next step
   • Substantial Equivalence (SE) letter: your device is cleared; proceed to market.
   • Not Substantially Equivalent (NSE): you may supplement, appeal, or convert to De Novo.
   • De Novo grant: FDA creates a new Class II regulation/product code and your device is the predicate for future 510(k)s.  
9. Post-clearance obligations kick in immediately
   Update device listing, maintain QSR compliance, file eMDRs for reportable adverse events, and manage any corrections or removals under 21 CFR 806. FDA inspections typically follow within the first production cycle, so keep design history and production records audit-ready. 

The Class II pathway is designed to be predictable—if you anchor your project to the right predicate (or De Novo logic), generate rock-solid performance evidence, and deliver a complete eSTAR dossier. Treat each FDA communication as a collaboration, not a hurdle, and clearance becomes a milestone on a well-mapped critical path rather than a gamble. 

Achieve FDA clearance for your class 2 medical device with Qualityze 

Even a textbook-perfect 510(k) can stall if design-history files, risk logs, or test reports live in a maze of shared drives and email threads. Qualityze EQMS removes that friction by giving you a single, validated workspace that aligns every Class 2 requirement—general and special—under one audit-ready roof. 

End-to-end design control
Qualityze Design & Document control systems map each user’s need, engineering requirement, and verification test into an unbroken trace matrix. When reviewers ask for “evidence that the flow-rate accuracy test mitigates Hazard HZ-05,” you can export the exact protocol, results, and approval signature in seconds. 

Risk management woven into the workflow
Built-in ISO 14971 templates let teams capture hazards, assign mitigations, and link them directly to test results or software code commits. The risk score updates automatically as new failure data arrive, ensuring the risk analysis you attach to eSTAR is always the latest—not last quarter’s PDF. 

eSTAR-ready outputs
Whether you pursue a Traditional, Special, or Abbreviated 510(k), Qualityze can compile DHF artifacts, labeling, biocompatibility reports, and declarations of conformity into structured folders that drop straight into FDA’s eSTAR template—minimizing Refuse-to-Accept surprises. 

Built-in compliance controls
• 21 CFR 820 process flows with electronic signatures and full audit trails
• Automatic UDI field population for labeling reviews
• Complaint, CAPA, and Nonconformance modules that feed post-market surveillance metrics—so the first FDA inspection after clearance feels routine, not risky. 

Post-market and eMDR support
• Complaint, CAPA, and Nonconformance modules capture every field required by FDA’s electronic Medical Device Reporting (eMDR) schema.
• Automated hand-offs generate an XML file compatible with the FDA ESG gateway or your preferred third-party eMDR submission service—so you can transmit mandatory reports without reinventing a workflow.
• Built-in dashboards surface event trends early, feeding risk files and management reviews. 

Built-in compliance controls
• 21 CFR 820 process flows with electronic signatures and full audit trails
• Automatic UDI field population for labeling reviews
• Real-time readiness dashboards that flag outstanding tasks against MDUFA timelines 

Expert implementation & validation
Qualityze arrives pre-validated to FDA software-assurance expectations, and our implementation team maps workflows to your current SOPs, shortening time to go-live without forcing a cultural upheaval.  

Conclusion

Class II devices occupy the FDA’s “moderate-risk” middle ground: demanding enough to warrant device-specific special controls yet streamlined compared with the extensive Premarket Approval process reserved for Class III. By confirming your product’s classification early, engaging FDA in a Pre-Submission to vet your predicate or De Novo logic, and compiling a complete, eSTAR-formatted 510(k) backed by robust design-control evidence, clearance becomes a predictable engineering milestone rather than a regulatory cliffhanger. 

Layering an EQMS such as Qualityze on top of that framework ensures every DHF artifact, risk record, and test report is traceable, current, and audit-ready—before the reviewer even opens your file. With clear processes, real-time dashboards, and built-in compliance controls, you can move from prototype to cleared product on schedule, keep post-market obligations under control, and focus on what matters most: delivering safe, effective technology to patients and clinicians who rely on it. 

Ready to turn down months of document chase to gain control and get a predictable, audit-ready timeline? Schedule a discovery call and see how Qualityze turns Class 2 compliance simpler for you—long before your device reaches the reviewer’s desk.